Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure
Author(s)
Morten Johnsen, PhD1, Oskar Ström, PhD2, Jane Skjøth-Rasmussen, MD, PhD3, Aida Muhic, MD3, Slávka Lukacova, MD, PhD4, Marc Massetti, PharmD, MSc5, Anais RAGON, PharmD, MSc5, Celine Aubin, PharmD, MSc5.
1Quantify Research, Copenhagen, Denmark, 2Quantify Research, Stockholm, Sweden, 3University Hospital of Copenhagen, Copenhagen, Denmark, 4Aarhus University Hospital, Aarhus, Denmark, 5Servier International, Suresnes, France.
1Quantify Research, Copenhagen, Denmark, 2Quantify Research, Stockholm, Sweden, 3University Hospital of Copenhagen, Copenhagen, Denmark, 4Aarhus University Hospital, Aarhus, Denmark, 5Servier International, Suresnes, France.
Presentation Documents
OBJECTIVES: Grade 2 IDH-mutant (mIDH) glioma is a slow progressing brain tumour, typically affecting working-age adults who can live with the disease for many years. This study aimed to estimate patient’s income-trajectories from diagnosis by radiotherapy/chemotherapy (RT/CT) exposure.
METHODS: Individual data for patients diagnosed with grade 2 mIDH glioma between 2010-2022 and not in immediate need of RT/CT were retrieved from Danish national administrative registers. Patient total income (earnings + public benefits, 2023€) was tracked from diagnosis until March 2024, emigration, or death and stratified by exposure to RT/CT over the study period.
RESULTS: Two-hundred and thirty-seven patients were included. Mean age at diagnosis was 40.3 years and median follow-up time was 6.1 (Q1-Q3: 3.8-8.9) years, with 220, 119, and 38 patients still followed at 2, 6, and 10 years, respectively. Hereof, 21%, 44%, and 50% had received RT/CT. Pre-diagnosis, patients' median annual income was €43,747, including €249 in public benefits. After diagnosis, patients without RT/CT exposure had median annual earnings of €43,420, €41,016, and €38,464 and received €2,472, €2,835, and €3,484 in benefits at 2, 6, and 10 years. Concurrently, patients who received RT/CT consistently had lower median earnings at €31,329, €23,306, and €17,992 - a 28%, 43%, and 53% decrease compared to those who did not receive RT/CT - whilst the median amount of received benefits progressively increased to €11,413, €24,263, and €27,918 respectively.
CONCLUSIONS: Overall, income of Danish Grade 2 mIDH glioma patients is relatively stable following diagnosis thanks to increasing public benefits, limiting the impact of reduced earnings. This is especially true in patients who receive RT/CT where these benefits represented 61% of the patients’ income 10 years after diagnosis, a substantial increase compared to the 0.6% before diagnosis. These findings warrant further research to compare them to the general population.
METHODS: Individual data for patients diagnosed with grade 2 mIDH glioma between 2010-2022 and not in immediate need of RT/CT were retrieved from Danish national administrative registers. Patient total income (earnings + public benefits, 2023€) was tracked from diagnosis until March 2024, emigration, or death and stratified by exposure to RT/CT over the study period.
RESULTS: Two-hundred and thirty-seven patients were included. Mean age at diagnosis was 40.3 years and median follow-up time was 6.1 (Q1-Q3: 3.8-8.9) years, with 220, 119, and 38 patients still followed at 2, 6, and 10 years, respectively. Hereof, 21%, 44%, and 50% had received RT/CT. Pre-diagnosis, patients' median annual income was €43,747, including €249 in public benefits. After diagnosis, patients without RT/CT exposure had median annual earnings of €43,420, €41,016, and €38,464 and received €2,472, €2,835, and €3,484 in benefits at 2, 6, and 10 years. Concurrently, patients who received RT/CT consistently had lower median earnings at €31,329, €23,306, and €17,992 - a 28%, 43%, and 53% decrease compared to those who did not receive RT/CT - whilst the median amount of received benefits progressively increased to €11,413, €24,263, and €27,918 respectively.
CONCLUSIONS: Overall, income of Danish Grade 2 mIDH glioma patients is relatively stable following diagnosis thanks to increasing public benefits, limiting the impact of reduced earnings. This is especially true in patients who receive RT/CT where these benefits represented 61% of the patients’ income 10 years after diagnosis, a substantial increase compared to the 0.6% before diagnosis. These findings warrant further research to compare them to the general population.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE676
Topic
Economic Evaluation, Health Policy & Regulatory, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
Oncology